Skip to main content
. Author manuscript; available in PMC: 2020 Jan 3.
Published in final edited form as: Gynecol Oncol. 2019 Jun 19;154(2):420–425. doi: 10.1016/j.ygyno.2019.05.013

Table 2.

Kaplan-Meier 5-year disease-specific survival (N = 7914).

Variable Total (%) Asian (%) Caucasian (%) Log rank

Overall 46.4 54.1 46.1 0.001
Age
 ≥59 42.3 47.3 42.2 0.050
BMI (n = 6764)
 <25 44.5 49.4 44.2 0.024
 ≥25 43.6 65.6 43.2 0.004
Performance status
 0 51.4 55.9 51.3 0.047
 1 40.5 51.8 40.2 0.02
 2/3 27.8 40.7 27.4 0.77
FIGO stage
 I 89.0 89.1 89.0 0.69
 II 80.7 63.5 81.2 0.48
 III 43.4 47.9 43.2 0.18
 IV 25.5 36.9 25.0 0.045
Histology
 Serous 41.6 50.5 41.3 0.006
 Clear-cell 59.9 61.3 59.8 0.64
 Endometrioid 67.3 64.9 67.3 0.77
 Mucinous 55.8 77.8 54.4 0.34
 Adenocarcinoma 66.7 100.0 65.8 0.25
 NOS mixed 52.8 33.3 53.5 0.09
 Epithelial other 49.3 66.7 48.8 0.21
Tumor grade (differentiation)
 1 61.7 73.3 61.4 0.38
 2 43.1 41.3 43.2 0.98
 3 44.5 53.8 44.2 0.007
 Ungraded 64.1 68.3 63.6 0.42
Gross residual disease
 Yes 32.9 41.6 32.5 0.02
 No 58.9 64.9 58.7 0.03